drugset / Trial / NCT02490748

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer

NCT02490748

Phase 2 Active not recruiting 10 enrolled The First People's Hospital of Changzhou
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cervical cancer.

Timeline

Start
2015-07
Primary completion
2038-06
Completion
2040-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CIK cells Cell therapy Intravenous

Indications